The Five Ebola Virus Species: Zaire, Sudan, Bundibugyo, Tai Forest, Reston
A complete guide to all five recognised Ebola virus species — their discovery, geographic range, case fatality rates, and the critical differences that affect vaccine and treatment choices.
What Is a Species of Ebola Virus?
Ebola viruses belong to the genus Ebolavirus within the family Filoviridae (filoviruses). Within the genus, the International Committee on Taxonomy of Viruses (ICTV) currently recognises six species — five of which are named in this article, plus the recently identified Bombali ebolavirus. The original four species were characterised between 1976 and 2008; a fifth was identified in 2012, and Bombali was found in bats in 2018.
The distinction between species is not merely academic: different species have different case fatality rates, geographic distributions, susceptible animal hosts, and — critically — different responses to vaccines and treatments. An approved vaccine for Zaire ebolavirus does not protect against Sudan ebolavirus.
Species 1: Zaire Ebolavirus (EBOV)
Discovered: 1976, Yambuku, Democratic Republic of Congo (then Zaire)
CFR range: 60–90% (untreated), 25–40% (with modern treatment)
Geographic range: Central Africa (DRC, Republic of Congo, Gabon), with West Africa in 2014
Overview
Zaire ebolavirus is the most well-studied, most frequently occurring, and most lethal species. It is responsible for the majority of Ebola outbreaks including:
- The 1976 Yambuku index outbreak (88% CFR)
- The 1995 Kikwit outbreak
- The 2014–2016 West Africa epidemic (28,600+ cases)
- The 2018–2020 DRC Kivu outbreak (3,481 cases)
- Every DRC outbreak except the 2012 Orientale outbreak
Countermeasures
- Vaccine: rVSV-ZEBOV (Ervebo) — FDA approved, demonstrated ~100% efficacy in ring vaccination
- Second vaccine: Ad26.ZEBOV/MVA-BN-Filo (Zabdeno/Mvabea) — EU approved, two-dose heterologous regimen
- Treatments: Inmazeb (REGN-EB3) and Ebanga (ansuvimab) — both FDA approved
- This is the only ebolavirus species with approved vaccines and treatments
Species 2: Sudan Ebolavirus (SUDV)
Discovered: 1976, Nzara, Sudan (now South Sudan) — simultaneously with Zaire
CFR range: 41–65%
Geographic range: East/Central Africa (South Sudan, Uganda, DRC)
Overview
Sudan ebolavirus has caused at least 7 documented outbreaks, with the largest being:
- 2000–2001 Gulu, Uganda: 425 cases, 224 deaths — the largest Sudan ebolavirus outbreak in history
- 2004 Yambio, Sudan: 17 cases
- 2011 Luwero, Uganda: 1 case
- 2012 Kibaale, Uganda: 24 cases
- 2022 Mubende, Uganda: 164 cases, 55 deaths — the most recent outbreak
The Critical Gap: No Approved Vaccine
The 2022 Uganda outbreak exposed a glaring gap: no approved vaccine or specific treatment exists for Sudan ebolavirus. The rVSV-ZEBOV vaccine (Ervebo) used for Zaire does not protect against Sudan ebolavirus — the glycoproteins are too different for cross-protection.
During the 2022 outbreak, WHO and partners launched emergency vaccine trials of three Sudan ebolavirus vaccine candidates:
- ChAd3-Sudan (Oxford/IAVI)
- GamEvac-Combi (Gamaleya, Russia)
- An MVABATUK/rVSV-SUDV regimen
None of these trials completed before the outbreak ended. As of 2026, no Sudan ebolavirus vaccine has completed Phase 3 trials. CEPI pledged $200M in 2022 to accelerate development.
CFR vs Zaire
Sudan ebolavirus consistently shows lower CFR than Zaire ebolavirus in matched outbreaks — approximately 41–65% vs 60–90% for Zaire, untreated. The molecular basis for this difference is not fully understood but relates to differences in glycoprotein structure and immune evasion capability.
Species 3: Bundibugyo Ebolavirus (BDBV)
Discovered: 2007, Bundibugyo District, Uganda
CFR range: 25–47%
Geographic range: Uganda, DRC (limited outbreaks)
Overview
Bundibugyo ebolavirus was discovered in 2007 when samples from an outbreak in Uganda’s Bundibugyo District were sequenced and found to represent a new species. It has caused only two documented outbreaks:
- 2007 Bundibugyo, Uganda: 149 cases, 37 deaths (25% CFR — the lowest CFR of any ebolavirus species in a significant outbreak)
- 2012 Orientale Province, DRC: 77 cases, 36 deaths (47% CFR)
Lower Lethality
The significantly lower CFR of Bundibugyo ebolavirus compared to Zaire and Sudan strains makes it somewhat less terrifying, though still extremely dangerous. Its limited number of outbreaks provides insufficient data to fully characterise its epidemiological behaviour.
Species 4: Tai Forest Ebolavirus (TAFV)
Discovered: 1994, Taï National Park, Côte d’Ivoire (Ivory Coast)
Human cases: 1 (non-fatal)
Geographic range: Unknown (potentially Côte d’Ivoire / West Africa)
Overview
Tai Forest ebolavirus has the most limited documented human exposure of any Ebola species — only one known human case in history. In November 1994, a Swiss zoologist who performed a necropsy on a wild chimpanzee that had died of an unidentified illness in Taï Forest developed EVD. She was medically evacuated to Switzerland, received supportive care, and survived.
No secondary transmission occurred. The identification of the virus in the chimpanzee necropsy tissues, and in the researcher’s blood, confirmed this as a new ebolavirus species.
Significance
Despite only a single case, TAFV’s identification expanded the known geographic range of ebolaviruses to West Africa and established that wild chimpanzees can be bridge hosts for novel ebolavirus spillover.
Species 5: Reston Ebolavirus (RESTV)
Discovered: 1989, Reston, Virginia, USA (in imported macaques from the Philippines)
Human infections: Several (confirmed by serology)
Human disease: None documented — Reston ebolavirus does NOT cause disease in humans
Geographic range: Southeast Asia (Philippines, with historical presence in European/US lab settings)
Overview
Reston ebolavirus is the only Ebola species found outside Africa — and the only one that apparently does not cause clinical disease in humans. In 1989, monkeys at a primate quarantine facility in Reston, Virginia developed fatal hemorrhagic fever. Subsequent testing identified an Ebola-like virus in the monkeys.
Four facility workers were exposed and seroconverted (developed antibodies), proving they had been infected — but none developed any symptoms. Subsequent Reston events (1990 Virginia, 1992 Italy, 1996 Texas, 2008 Philippines pig farms) similarly showed no human disease despite exposure.
Why Isn’t Reston Deadly?
The mechanism by which Reston ebolavirus fails to cause disease in humans is an active area of research. It may relate to differences in the glycoprotein structure and its interaction with the human immune system. Reston virus is still classified as a BSL-4 pathogen due to theoretical risk of mutation toward pathogenicity.
Geographic Location
Reston is the only ebolavirus linked to Asia. Fruit bats in the Philippines (notably Acerodon jubatus and Pteropus vampyrus) have been found to carry antibodies, suggesting a similar bat reservoir dynamic in Southeast Asia.
The Sixth Species: Bombali Ebolavirus (BOMV)
Discovered: 2018, Sierra Leone (in Chaerephon pumilus insectivorous bats)
Human cases: None documented
Bombali ebolavirus was identified from insectivorous bats in Sierra Leone in 2018 — the first Ebola species found in an insectivorous bat (rather than fruit bat). No human or animal disease has been attributed to Bombali ebolavirus. Its public health significance is unknown.
Summary Comparison
| Species | Outbreaks | Max CFR | Human Vaccine | Human Treatment |
|---|---|---|---|---|
| Zaire | 20+ | 90% | ✅ Ervebo, Zabdeno/Mvabea | ✅ Inmazeb, Ebanga |
| Sudan | 7 | 65% | ❌ None approved | ❌ None approved |
| Bundibugyo | 2 | 47% | ❌ None approved | ❌ None approved |
| Tai Forest | 1 | 0% (survived) | — | — |
| Reston | Multiple | 0% (no human disease) | — | — |
| Bombali | 0 | — | — | — |
The key public health lesson: Ebola is not a single threat but a family of threats — and progress in countermeasures has been almost entirely focused on Zaire ebolavirus. The gaps for Sudan, Bundibugyo, and potentially novel species remain critical vulnerabilities in global health security.